OCGN Ocugen, Inc.
$0.70▼ -6.54%
Healthcare
Other
Volume 3.00M
Avg Volume (10D) 6.76M
Key Metrics & Fundamentals
Market Cap
$235.85M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.69 - 2.73
% vs 50 MA
-28.96%
% vs 200 MA
-48.10%
RSI-14
31.5
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.61
Free Cash Flow
-$12.22M
Gross Rev
$1.49M
Gross Profit
$1.49M
EBITDA
-$15.54M
COGS
–
Operating Exp
$17.93M
Operating Income
-$16.44M
EBIT
-$16.44M
Pretax Income
-$24.88M
Net Income
-$24.88M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Ocugen to Participate in Upcoming November Investor and Industry Conferences
GlobeNewswire · Oct 29, 2026 7:02 AM ET
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
GlobeNewswire · Oct 22, 2026 7:00 AM ET
Ocugen Signs MENA Licensing Deal for OCU400
MT Newswires · Oct 14, 2026 7:13 AM ET
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
GlobeNewswire · Oct 14, 2026 6:30 AM ET
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
GlobeNewswire · Oct 6, 2026 7:02 AM ET
Ocugen to Participate in Upcoming Scientific Conferences
GlobeNewswire · Sep 30, 2026 7:02 AM ET
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight
PR Newswire · Sep 29, 2026 10:31 AM ET
Ocugen to Participate in Upcoming October Investor and Industry Conferences
GlobeNewswire · Sep 29, 2026 7:02 AM ET
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
MT Newswires · Sep 25, 2026 1:57 PM ET
Ocugen Gets Provisional Approval for OCU400 in Bahamas
MT Newswires · Sep 25, 2026 8:55 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See OCGN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.